Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Antioxid Redox Signal ; 21(6): 819-34, 2014 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-24738702

RESUMO

AIMS: Storkhead box 1 (STOX1) is a winged-helix transcription factor that is implicated in the genetic forms of a high-prevalence human gestational disease, pre-eclampsia. STOX1 overexpression confers pre-eclampsia-like transcriptomic features to trophoblastic cell lines and pre-eclampsia symptoms to pregnant mice. The aim of this work was to evaluate the impact of STOX1 on free radical equilibrium and mitochondrial function, both in vitro and in vivo. RESULTS: Transcriptome analysis of STOX1-transgenic versus nontransgenic placentas at 16.5 days of gestation revealed alterations of mitochondria-related pathways. Placentas overexpressing STOX1 displayed altered mitochondrial mass and were severely biased toward protein nitration, indicating nitroso-redox imbalance in vivo. Trophoblast cells overexpressing STOX1 displayed an increased mitochondrial activity at 20% O2 and in hypoxia, despite reduction of the mitochondrial mass in the former. STOX1 overexpression is, therefore, associated with hyperactive mitochondria, resulting in increased free radical production. Moreover, nitric oxide (NO) production pathways were activated, resulting in peroxynitrite formation. At low oxygen pressure, STOX1 overexpression switched the free radical balance from reactive oxygen species (ROS) to reactive nitrogen species (RNS) in the placenta as well as in a trophoblast cell line. INNOVATION: In pre-eclamptic placentas, NO interacts with ROS and generates peroxynitrite and nitrated proteins as end products. This process will deprive the maternal organism of NO, a crucial vasodilator molecule. CONCLUSION: Our data posit STOX1 as a genetic switch in the ROS/RNS balance and suggest an explanation for elevated blood pressure in pre-eclampsia.


Assuntos
Proteínas de Transporte/genética , Homeostase/genética , Mitocôndrias/genética , Mitocôndrias/metabolismo , Óxido Nítrico/metabolismo , Pré-Eclâmpsia/genética , Pré-Eclâmpsia/metabolismo , Animais , Modelos Animais de Doenças , Metabolismo Energético , Feminino , Regulação da Expressão Gênica , Hipóxia , Masculino , Camundongos , Oxirredução , Placenta/metabolismo , Gravidez
2.
Hypertension ; 61(3): 662-8, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23357179

RESUMO

Preeclampsia (PE) is a common human-specific pregnancy disorder defined by hypertension and proteinuria during gestation and responsible for maternal and fetal morbimortality. STOX1, encoding a transcription factor, was the first gene associated with PE as identified by positional cloning approaches. Its overexpression in choriocarcinoma cells mimics the transcriptional consequences of PE in the human placenta. Here, we created transgenic mouse strains overexpressing human STOX1. Wild-type female mice crossed with transgenic male mice reproduce accurately the symptoms of severe PE: gestational hypertension, proteinuria, and elevated plasma levels of soluble fms-like tyrosine kinase 1 and soluble endoglin. Placental and kidney histology were altered. Symptoms were prevented or alleviated by aspirin treatment. STOX1-overexpressing mice constitute a unique model for studying PE, allow testing therapeutic approaches, and assessing the long-term effects of the preeclamptic syndrome.


Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Aspirina/uso terapêutico , Proteínas de Transporte/biossíntese , Placenta/metabolismo , Pré-Eclâmpsia/tratamento farmacológico , Animais , Proteínas de Transporte/efeitos adversos , Proteínas de Transporte/genética , Modelos Animais de Doenças , Endoglina , Feminino , Humanos , Peptídeos e Proteínas de Sinalização Intracelular/sangue , Rim/patologia , Masculino , Camundongos , Camundongos Transgênicos , Placenta/patologia , Pré-Eclâmpsia/etiologia , Pré-Eclâmpsia/genética , Gravidez , Índice de Gravidade de Doença , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA